Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02634606 · ClinicalTrials.gov registry record · Phase 3
Effects of a Supplement Derived From Palm Oil on Cholesterol Levels in the Blood
A Phase 3 study, sponsored by University of California, Los Angeles.
- Terminated
- Registry status
- Phase 3
- Development phase
- 13
- Enrollment target
NCT02634606 is a Phase 3 study that was terminated before completion, run by University of California, Los Angeles. The registered enrollment target is 13 participants.
The verdict
NCT02634606, a Phase 3 study, was terminated before completion, sponsored by University of California, Los Angeles.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 13 participants
- Enrollment target
Study Summary
Elevated blood cholesterol, and particularly LDL cholesterol, is a risk factor for heart disease. Tocotrienols are naturally-occurring compounds in foods that may have beneficial effects on blood cholesterol. Tocotrienols are members of the vitamin E family, and are found in barley, oats, rye, coconut oil and rice bran oil, but the richest source of tocotrienols is palm oil. Certain of these tocotrienols have been shown to be effective in lowering LDL (or 'bad') cholesterol, with no adverse effects on the HDL (or 'good') cholesterol. The purpose of this study is to determine the effects of a palm-oil derived tocotrienol supplement on blood cholesterol, and particularly LDL cholesterol, in individuals who are taking statins, and have either elevated or normal cholesterol levels. Study subjects will consume a palm-oil derived supplement of tocotrienol for 3 months to determine its effects on LDL cholesterol.
Interventions
- DRUG Sugar Pill
- DRUG Gamma Delta Tocotrienols - Low Dose
- DRUG Gamma Delta Tocotrienols - High Dose
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2011-03-22 |
| Est. Completion | 2015-11-13 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02634606
The ClinicalTrials.gov registry entry for NCT02634606 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, Los Angeles, which has 897 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Sugar Pill is the first listed.
NCT02634606 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02634606 about?
NCT02634606 is a clinical study titled "Effects of a Supplement Derived From Palm Oil on Cholesterol Levels in the Blood". Elevated blood cholesterol, and particularly LDL cholesterol, is a risk factor for heart disease. Tocotrienols are naturally-occurring compounds in foods that may have beneficial effects on blood cholesterol. Tocotrienols are members of the vitamin E family, and are found in barley, oats, rye, cocon...
What is the current status of trial NCT02634606?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 13 participants. The study started on 2011-03-22. Estimated completion is 2015-11-13.
What interventions are being tested in trial NCT02634606?
The interventions under investigation include: Sugar Pill (DRUG), Gamma Delta Tocotrienols - Low Dose (DRUG), Gamma Delta Tocotrienols - High Dose (DRUG).
Who is sponsoring clinical trial NCT02634606?
This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.